title: Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
abstract: OBJECTIVE
  To test the efficacy of levofloxacin-based second-line therapy for resistant Helicobacter pylori infection.
  
  
  METHODS
  One hundred and six patients who failed H. pylori eradication were randomized to receive (i) lansoprazole 30 mg, amoxicillin 1 g, levofloxacin 500 mg, all given twice daily for 7 days (LAL); or (ii) lansoprazole 30 mg twice daily, metronidazole 400 mg thrice daily, bismuth subcitrate 120 mg and tetracycline 500 mg four times daily for 7 days (quadruple). Post-treatment H. pylori status was determined by (13)C-urea breath test.
  
  
  RESULTS
  Intention-to-treat and per-protocol H. pylori eradication rates were 57/60% for the LAL group and 71/76% for the quadruple group respectively. Metronidazole, clarithromycin, amoxicillin and levofloxacin resistance were found in 76%, 71%, 0% and 18% of patients, respectively. Levofloxacin resistance led to treatment failure in the LAL group. For patients with dual resistance to metronidazole and clarithromycin, the eradication rates were 79% in the LAL group (levofloxacin-sensitive) and 65% in the quadruple group (P=0.34).
  
  
  CONCLUSIONS
  Lansoprazole, amoxicillin plus levofloxacin second-line therapy is comparable with quadruple therapy in efficacy. Subjects, especially those with dual resistance to metronidazole and clarithromycin, may consider levofloxacin-based therapy for levofloxacin-sensitive strains.
authors.affiliation: Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
authors.forename: W M
authors.initials: WM
authors.lastname: Wong
authors.forename: Q
authors.initials: Q
authors.lastname: Gu
authors.forename: K-M
authors.initials: KM
authors.lastname: Chu
authors.forename: Y K
authors.initials: YK
authors.lastname: Yee
authors.forename: F M Y
authors.initials: FM
authors.lastname: Fung
authors.forename: T S M
authors.initials: TS
authors.lastname: Tong
authors.forename: A O O
authors.initials: AO
authors.lastname: Chan
authors.forename: K C
authors.initials: KC
authors.lastname: Lai
authors.forename: C K
authors.initials: CK
authors.lastname: Chan
authors.forename: B C Y
authors.initials: BC
authors.lastname: Wong
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006723:Hong Kong; D006801:Humans; D064747:Lansoprazole; D064704:Levofloxacin; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D009942:Organometallic Compounds; D013752:Tetracycline / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D009942:Organometallic Compounds; D064747:Lansoprazole; D008795:Metronidazole; D064704:Levofloxacin; D000658:Amoxicillin; D015242:Ofloxacin; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole